Jade Biosciences, Inc. JBIO
16.40 USD +0.80 (+5.13%)
At closeNov 11, 2026, 4:06 AM EST
16.20 -0.20 -1.22%
Pre-market · Nov 11, 4:06 AM ET
15.26 Day range 16.56
8.95 52-week range 28.00
- YTD
- +6.29%
- 1 year
- +76.72%
- Market cap
- 1.04B
- EPS (ttm)
- -1.92
- Shares out
- 63.60M
- Forward P/E
- -6.16
- YTD return
- +6.29%
- 1-year return
- +76.72%
- Volume
- 895.17K
- Avg volume
- 900.31K
- Open
- 15.37
- Previous close
- 15.60
- Day's range
- 15.26 – 16.56
- 52-week range
- 8.95 – 28.00
- Analysts
- Strong Buy
- Price target
- 50.13 (+205.6%)
- Earnings date
- Nov 12, 2026
5D +1.38 (+9.19%)
Key statistics
- Enterprise value
- 532.31M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 461.20M
- Total debt
- 1.39M
- Return on equity
- 0.00%
- Short % of float
- 21.57%
- 50-day average
- 15.70
- 200-day average
- 18.21
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 50.13 +205.6% upside
Now 16.40
- Target (low)
- 40.00
- Target (mean)
- 50.13
- Target (high)
- 77.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy0
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.78642.
Financials — quick view
JBIO Revenue — quarterly 0
JBIO Net income — quarterly -55.77M
JBIO EPS — quarterly -0.76
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.73 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.63642 | -0.76 | -0.12 | -19.42% |
| May 7, 2026 | Mar 31, 2026 | -0.52 | -0.57 | -0.05 | -9.62% |
| Mar 6, 2026 | Dec 31, 2025 | -0.45 | -0.45 | 0.00 | 0.00% |
| Nov 14, 2025 | Sep 30, 2025 | -0.57 | -0.48 | +0.09 | +15.79% |
| Aug 14, 2025 | Jun 30, 2025 | -0.43 | -0.86 | -0.43 | -100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | BTIG | reit | Buy | Buy |
| Oct 1, 2026 | Wedbush | reit | Outperform | Outperform |
| Oct 1, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 11, 2026 | Wedbush | main | Outperform | Outperform |
| Aug 10, 2026 | BTIG | main | Buy | Buy |
| Jun 15, 2026 | UBS | init | — | Buy |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- jadebiosciences.com
News
Your note
Sign in to keep a note on JBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALTA ELIZABETH | Officer | Stock Award(Grant) | Feb 11, 2026 | 28,125 |
| DAHMS BRADFORD D | Chief Financial Officer | Stock Award(Grant) | Feb 11, 2026 | 37,813 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Oct 5, 2025 | 0 |
| FROHLICH TOM | Chief Executive Officer | Stock Award(Grant) | Feb 11, 2026 | 86,331 |
| KING ANDREW JAMES | Officer | Stock Award(Grant) | Feb 11, 2026 | 386,113 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.35% | 9,126,877 | 149.68M | Jun 29, 2026 |
| Jupiter Topco LLC | 9.86% | 6,273,262 | 102.88M | Jun 29, 2026 |
| Fairmount Funds Management LLC | 7.16% | 4,553,494 | 74.68M | Jun 29, 2026 |
| RA Capital Management, L.P. | 5.77% | 3,671,083 | 60.21M | Jun 29, 2026 |
| Venrock Adviser, LLC | 5.06% | 3,220,364 | 52.81M | Jun 29, 2026 |
| Bellevue Group AG | 4.81% | 3,057,996 | 50.15M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.70% | 1,714,640 | 28.12M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.67% | 1,699,343 | 27.87M | Jun 29, 2026 |
| Franklin Value Investors Trust-FRANKLIN SMALL CAP VALUE FUND | 2.22% | 1,412,559 | 23.17M | Jul 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.87% | 1,191,884 | 19.55M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.62% | 1,032,642 | 16.94M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.57% | 1,000,000 | 16.40M | Sep 29, 2026 |